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Assessment of Cancer Cell Line Representativeness
Using Microarrays for Merkel Cell Carcinoma
Kenneth Daily1, Amy Coxon1, Jonathan S. Williams1, Chyi-Chia R. Lee2, Daniel G. Coit3, Klaus J. Busam4 and
Isaac Brownell1,5
When using cell lines to study cancer, phenotypic similarity to the original tumor is paramount. Yet, little has
been done to characterize how closely Merkel cell carcinoma (MCC) cell lines model native tumors. To determine
their similarity to MCC tumor samples, we characterized MCC cell lines via gene expression microarrays. Using
whole transcriptome gene expression signatures and a computational bioinformatic approach, we identified
significant differences between variant cell lines (UISO, MCC13, and MCC26) and fresh frozen MCC tumors.
Conversely, the classic WaGa and Mkl-1 cell lines more closely represented the global transcriptome of MCC
tumors. When compared with publicly available cancer lines, WaGa and Mkl-1 cells were similar to other
neuroendocrine tumors, but the variant cell lines were not. WaGa and Mkl-1 cells grown as xenografts in mice
had histological and immunophenotypical features consistent with MCC, whereas UISO xenograft tumors were
atypical for MCC. Spectral karyotyping and short tandem repeat analysis of the UISO cells matched the original
cell line’s description, ruling out contamination. Our results validate the use of transcriptome analysis to assess
the cancer cell line representativeness and indicate that UISO, MCC13, and MCC26 cell lines are not
representative of MCC tumors, whereas WaGa and Mkl-1 more closely model MCC.
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INTRODUCTION
Cancer cell lines are essential tools for modeling human
malignancy. However, many factors can alter the representa-
tiveness of a cultured cell line. Some differences to the native
tumor are expected with cells grown in culture because of the
absence of vascular stroma and tumor architecture. Additional
discrepancies can arise because of the evolution of atypical
subclones that possess in vitro growth advantages, genomic
instability associated with repeated passaging, alterations
secondary to microbial infections in culture, and contamina-
tion from other cell lines (Barallon et al., 2010; Capes-Davis
et al., 2010). Phenotypic dissimilarity to the original tumor
affects the relevance of a cell line as an experimental model.
Thus, systematic comparison of cell lines to the cancers they
are modeling is critical.
Microarray expression profiles have been used to compare
cancer cell lines to native tumors for a number of cancer types
(Khan et al., 2001; Wang et al., 2006; Carlson et al., 2007; Li
et al., 2008; Gillet et al., 2011; Barretina et al., 2012). In some
cases, extensive transcriptomic differences were found between
cell lines and primary tumors (Wang et al., 2006; Li et al.,
2008). These studies illustrate the utility of microarray expres-
sion profiling in characterizing cancer cell lines; however, the
implications of expression profile differences on the biological
representativeness of cells lines were not assessed.
Merkel cell carcinoma (MCC) is an aggressive neuroendo-
crine skin cancer (Toker, 1972; Maricich et al., 2009, 2012).
The risk of developing MCC is associated with UV light
exposure, advanced age, and immunosuppression (Hodgson,
2005; Becker, 2010). Approximately 80% of MCC tumors
have DNA of the Merkel cell polyomavirus (MCV) clonally
integrated into their genome (Feng et al., 2008). The MCV T
antigen is thought to be important in MCC carcinogenesis
(Houben et al., 2010); however, it is unclear whether the
presence or absence of integrated MCV alters the outcome or
course of MCC.
Like most solid malignancies, diagnosis of MCC relies on
histopathological examination of tumor tissue. MCC shares a
number of histopathological characteristics with other tumors
of neuroendocrine origin. For example, both MCC and small-cell
lung cancer (SCLC) are frequently composed of morphologically
similar, small, round cells that frequently express chromogranin
(CHGA), synaptophysin (SYP), and neuron-specific enolase
(ENO2). In contrast, immunostaining for cytokeratin 20 (KRT20)
is more specific for MCC, whereas thyroid transcription
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factor-1 is a marker of SCLC (Leech et al., 2001; Pulitzer et al.,
2009).
A growing number of MCC tumor cell lines are available
(Rosen et al., 1987; Leonard et al., 1993; Ronan et al., 1993;
Moll et al., 1994; Leonard et al., 1995; Krasagakis et al.,
2001). Most MCC cell lines grow in suspension, express MCC
immunomarkers, and demonstrate dense core granules on
ultrastructural analysis. MCC cell lines with these typical
features, such as WaGa and Mkl-1, are termed ‘‘classic’’
(Ronan et al., 1993; Leonard et al., 1993; Van Gele et al.,
2004). In contrast, ’’variant’’ MCC cell lines like UISO-MCC-1
(henceforth referred to as UISO) (Ronan et al., 1993), MCC13,
and MCC26 (Leonard et al., 1995) grow adherently in culture,
lack typical markers on immunostaining, and have reduced
numbers of neurosecretory granules. The majority of classic
MCC cell lines test positive for MCV, whereas most variant
cell lines are MCV negative. Little has been done to assess the
representativeness of either classic or variant MCC cell lines.
Here we apply computational and experimental methods to
compare MCC cell line transcriptomes with each other, with
fresh tumor tissue, and with other cancer cells in order to
examine their representativeness. Using these approaches, we
find that three variant cell lines are not characteristic of MCC,
whereas three classic MCC cell lines more closely represent
native MCC tumors. We validate the nonrepresentative biol-
ogy of UISO cells by demonstrating atypical in vivo growth in
a xenograft tumor model.
RESULTS
Variant cell lines cluster distinctly from MCC tumors and classic
MCC cell lines
In order to test how well they modeled MCC, we analyzed
global RNA expression in six MCC lines: the variant lines
UISO, MCC13, and MCC26, and the classic lines WaGa
(Houben et al., 2010), Mkl-1 (Rosen et al., 1987), and a newly
established MCC cell line SK-MC01 (hereafter MC01). We
also analyzed global RNA expression from 23 MCC and 9
SCLC fresh frozen tumor samples.
We performed hierarchical clustering to identify groups of
samples with similar global gene expression profiles (Figure 1a).
The variant cell line samples formed a group divergent from the
MCC tumors, SCLC tumors, and the classic WaGa, Mkl-1, and
MC01 samples, indicating that these cell lines are distinct from
both native tumors and the more typical MCC cells. Furthermore,
the UISO samples clustered separately from the other variant cell
lines, MCC13 and MCC26. In contrast to the variant lines,
WaGa, Mkl-1, and MC01 cells clustered with the MCC tumor
samples. These differences in gene expression can also be visua-
lized in a principal components analysis projection (Figure 1b
and Supplementary Figure S1 online). In the principal compo-
nents analysis, expected differences due to in vitro growth appear
to contribute to the separation between cultured cells and fresh
frozen tumor samples along the second principal component.
Global gene expression differences between the MCC cell lines
and tumor samples
To identify RNA expression differences, we performed differ-
ential expression analysis between the MCC tumor samples
and each group of cell lines: classic (WaGa, Mkl-1, and
MC01), variant (MCC13 and MCC16), and UISO. Figure 2
depicts a Venn diagram of the differentially expressed probe
sets in the comparison of each group to the tumor samples. In
total, 1,023 probe sets showed common differential expres-
sion between the tumor samples and all three groups. In line
with our prior results, many more probe sets were uniquely
differentially expressed between the MCC tumor samples and
UISO cells (4,223) or the other variant lines (4,103) than
between the MCC tumors and the classic cell lines (938). To
quantify the overall similarity of cell line expression profiles to
MCC tumor samples, Spearman’s rank correlation coefficients
between individual expression profiles of MCC cell lines and
tumor samples were computed (Supplementary Figure S2
online). The classic samples were similar to tumor samples
(median correlation¼0.83). UISO cells were less similar
(median correlation¼ 0.66), as were the other variant lines
(median correlation¼0.68).
Virus status of MCC tumors does not influence gene expression
comparisons
Despite having varied clinical features, the MCC tumor
samples analyzed in this study were remarkably homogeneous
at the RNA expression level. We observed no significantly
differentially expressed probe sets when comparing samples
based on clinically relevant phenotypes such as tumor site
(primary skin vs. metastasis), if the patient ultimately had a
recurrence, or tumor stage (stage 1–2 vs. stage 3, coded as
early vs. late; Supplementary Table S1 online). We found
relatively few (214) significantly differentially expressed probe
sets between MCV-positive and -negative tumors (Supplemen-
tary Table S2 online), including previously described differ-
ences in TP53 and RB1 expression (Bhatia et al., 2010; Sihto
et al., 2011; Waltari et al., 2011; Harms et al., 2013).
Consistent with this high degree of similarity, there was little
difference in the correlation values for each cell line when
compared independently with MCV-positive or MCV-negative
tumors (Supplementary Table S3 online). These observations
suggest that clinical differences and MCV status are not driving
the divergent expression profile observed in the MCV-negative
(Guastafierro et al., 2013) variant cell lines.
Predicted functional differences between MCC cell lines and
tumor samples
Having identified significant differences between the variant
MCC cell lines and the tumor samples at the single gene level,
we sought to identify functional differences at the pathway
level. To identify pathways that are significantly differentially
expressed between MCC cell lines and tumor samples, we
applied Gene Set Enrichment Analysis (Subramanian et al.,
2005) using the differential expression data and pathway gene
sets taken from the KEGG (Kyoto Encyclopedia of Genes and
Genomes) database (Kanehisa and Goto, 2000). We assessed
pathway enrichment in the differentially expressed genes
comparing MCC tumors to UISO cells, variant cell lines,
and classic cell lines (Supplementary Table S4 online).
Although enrichment of any given pathway requires experi-
mental validation, Gene Set Enrichment Analysis often
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accurately reveals biological schemes. It is therefore note-
worthy that the gene expression differences between UISO
cells and MCC tumors show concordant changes in processes
central to oncogenesis such as DNA replication and RNA
processing (spliceosome). Despite having a similarly large
number of differentially expressed probe sets as UISO, the
other variant cell lines had very few differentially expressed
pathways, with only the proteasome pathway showing high
enrichment. On the other hand, highly differentially expressed
pathways between MCC tumors and the classic cell lines
could be attributed to cultured cells lacking both stromal
interactions (focal adhesion and extracellular matrix interac-
tions) and an immune infiltrate (multiple autoimmune, inflam-
matory, and infectious pathways). Taken together, the Gene
Set Enrichment Analysis results further suggest that UISO cells
are less appropriate to use as a model for MCC but give little
insight into the large differences between MCC tumors and the
other variant cell lines.
Classification of MCC cell lines using tumor samples
As our analyses suggested that variant cell lines were similarly
distinct from both skin and lung neuroendocrine tumors, we
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Figure 1. Variant cell lines cluster separately from Merkel cell carcinoma (MCC) tumors and classic MCC cell lines. (a) Hierarchical clustering of microarray
expression data from MCC cell lines and MCC and small-cell lung cancer (SCLC) frozen tumor samples. Average linkage was applied for merging clusters
to the variance-filtered probe set expression values. One minus the Spearman’s correlation was used as a dissimilarity metric. MCV positive, red; MCV negative,
blue; not tested, black. (b) Principal component analysis (PCA) of microarray expression data from MCC cell lines and MCC and SCLC tumor samples was
performed with variance-filtered probe set expression values for each sample. The variance in the expression data accounted for by the first three principal
components are 26, 22, and 7%.
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sought to test whether the variant lines would be classified as
MCC or SCLC using a random forest machine learning
classifier trained on expression signatures of the fresh frozen
tumor samples (see Supplementary Methods online). This
classifier was applied to the expression signatures of the
MCC cell lines. The trained model strongly classified all
classic cell lines as MCC (over 80% probability, Table 1).
None of the variant cell lines were strongly classified as MCC
or SCLC, indicating they resemble SCLC as much as they
resemble MCC.
Classification of MCC cell lines using the Cancer Cell Line
Encyclopedia
As the gene expression of variant cell lines did not resemble
MCC tumors or more typical classic MCC cell lines, we
assessed their distinctness using data from the Cancer Cell
Line Encyclopedia (CCLE) (Barretina et al., 2012) to compare
MCC cell line expression data with a broad set of cancer cell
lines. We selected a set of eight cancer types from the CCLE
that were common malignancies or shared some feature with
MCC (from the skin, neuroendocrine, or neuroectodermal) to
analyze with the MCC cell lines.
A random forest classifier was constructed using the
selected CCLE lines and the Mkl-1 and WaGa cell lines
(grouped as an MCC class) to classify the variant cell lines (see
Supplementary Methods online). The resulting random forest
did not classify the UISO samples as MCC (1% probability).
They were classified with nearly equal probability for a
number of tumor types, including melanoma, hepatocellular,
breast, and lung carcinomas (Supplementary Table S5 online).
The variant samples MCC13 and MCC26 were classified more
strongly as MCC (up to 18% probability) but were similarly
classified to other cancer types as UISO. Held out WaGa or
Mkl-1 samples were strongly classified as MCC (70% prob-
ability, Supplementary Table S6 online). Using principal
components analysis visualization, we observed that WaGa
and Mkl-1 samples clustered near neuroendocrine (SCLC) and
neuroectodermal (Ewing’s sarcoma) samples. As expected,
UISO samples clustered away from the neuroendocrine
tumors, whereas the MCC13 and MCC26 samples cluster in
between the UISO and classic samples (Figure 3). These
findings reinforce that UISO, MCC13, and MCC26 do not
resemble typical MCC cell lines.
Immunohistochemical analysis of MCC xenograft tumors
To confirm that the distinct expression profile observed in
cultured UISO cells correlates with an atypical tumor pheno-
type in vivo, we grew xenograft tumors with UISO, WaGa,
and Mkl-1 cells in immunocompromised mice. Histologically,
WaGa tumors showed features consistent with MCC: sheets of
tumor cells with scant cytoplasm, rounded nuclei, inconspic-
uous nucleoli, stippled chromatin patterning, and a brisk
mitotic rate (Figure 4). WaGa xenograft tissue also resembled
the immunophenotype of typical MCC tumors with positive
immunostaining for the neuroendocrine markers chromogra-
nin, NCAM1 (CD56), and ENO2. The MCC markers KRT20
and pan-cytokeratin (AE1/AE3) both stained with a character-
istic paranuclear dot pattern in WaGa tumors, and the SCLC
marker thyroid transcription factor-1 was negative. As a MCV-
positive cell line (Houben et al., 2010), WaGa xenografts
stained with CM2B4, an anti-MCV T antigen antibody. Mkl-1
tumors showed immunohistochemical features similar to
WaGa tumors, consistent with typical MCC tumors (data not
shown).
In contrast, UISO xenografts did not resemble typical MCC
tumors. The UISO tumors had abundant fibrovascular stroma
Tumor.UISO
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266
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Figure 2. Compared with Merkel cell carcinoma (MCC) tumors, variant MCC
cell lines have more differentially expressed genes than classic MCC cell lines.
A Venn diagram showing the number of probe sets commonly differentially
expressed when comparing the MCC tumor samples with UISO and other
variant (MCC13 and MCC26) and classic (WaGa and Mkl-1) cell lines. Only
probe sets with an absolute fold change of 42 and a q-value of o0.05 are
counted (total: 13,329 probe sets).
Table 1. Random forest classification of MCC cell lines
MCC SCLC
WaGa 0.89 0.11
Mkl-1 0.85 0.15
MC01 0.83 0.17
MCC13 0.43 0.57
MCC26 0.40 0.60
UISO 0.43 0.57
Abbreviations: MCC, Merkel cell carcinoma; SCLC small-cell lung cancer.
A random forest classifier was trained using the microarray probe set
expression data for the 23 MCC and 9 SCLC tumor samples. The classifier
was then applied to the MCC cell lines, and the average class prediction
was determined for each of the MCC cell lines (over sample replicates).
The class assignment (MCC and SCLC) probability is given as the fraction of
trees in the random forest voting for each class. The values shown are the
average of six replicates for Mkl-1, WaGa, and UISO, three replicates for
MCC13 and MCC16, and one replicate for MC01. Bold values indicate
maximum average class probability for each cell line.
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separating islands of tumor cells with large, irregular, hyper-
chromatic nuclei, irregular dendritic processes, and perinuc-
lear clearing. UISO tumors lacked staining for MCC markers
such as chromogranin, KRT20, and pan-cytokeratin. However,
there was focal staining for NCAM1 and ENO2. Staining for
thyroid transcription factor-1 and CM2B4 was negative, as
expected. Staining was also negative for S100, CD34, and
KRT7 (data not shown). Overall, UISO xenograft tumors were
not diagnostic for MCC and were most consistent with a
poorly differentiated neuroendocrine tumor possessing sarco-
matoid features.
The UISO cell line is not contaminated
Cross-contamination with another cancer cell line could
explain why UISO cells are not representative of MCC.
Fortunately, early cytogenetic characterizations of UISO cells
and the availability of low-passage cells allowed us to confirm
the provenance of the contemporary cell line. We performed
spectral karyotyping (SKY) on UISO cells to compare with
previously reported cytogenetic changes (Van Gele et al.,
1998, 2002). On metaphase spreads, several recurrent
chromosomal changes were identified consistent with prior
studies, including a small insertion at 1p36.2, a cryptic
insertion or duplication on 6q, a dicentric chromosome 8,
and a small heterogeneous ring chromosome (Figure 5). A new
t(10;19) translocation was also observed. Conservation of
these features strongly supports the present day cell line being
of the same origin as the UISO cells used in earlier
publications.
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Figure 3. Among multiple cancer cell lines, variant cell lines are distinct from
classic Merkel cell carcinoma (MCC) cell lines, as well as other
neuroendocrine lines. Principal component analysis of microarray expression
data from MCC cell lines and cell lines from the Cancer Cell Line Encyclopedia
was computed from variance-filtered probe set expression values for each
sample. The variance in the expression data accounted for by components 1
and 2 are 8% and 5%, respectively. Adeno, adenocarcinoma; Ewings, Ewing’s
sarcoma; SCC, squamous cell carcinoma; SCLC, small-cell lung cancer.
WaGa WaGa
CK
20
Pa
n 
CK
TT
F-
1
CM
2B
4
N
SE
CD
56
Ch
ro
m
og
ra
in
H
&E
UISO UISO
Figure 4. UISO xenograft tumors are histologically atypical for Merkel cell carcinoma (MCC). Representative images of hematoxylin and eosin staining (H&E)
and immunohistochemical staining of WaGa and UISO xenograft tumors in NOD/SCID mice. Scale bar¼ 100mm. Pan CK, pan-cytokeratin; TTF-1, thyroid
transcription factor-1.
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To confirm this, we obtained archived early-passage cells
directly from the laboratory that established the UISO cell line
(Ronan et al., 1993). Short tandem repeat (STR) profiling
(Masters et al., 2001) was performed using 16 markers (see
Supplementary Methods online) on all of the MCC cell lines
used here. The STR fingerprint of the UISO cell line was
identical to the early-passage UISO cells (Supplementary
Table S7 online). Moreover, none of the cell lines were similar
to any cell line available in the major cell line databases
(ATCC, DSMZ, JCRB), indicating that no cross-contamination
with an STR-characterized cell line occurred.
DISCUSSION
Characterization of tumor cell lines is important in developing
appropriate and representative in vitro models for the study of
cancer. Here we found that three variant MCC cell lines were
not representative of MCC tumors based on multiple com-
parative analyses of global gene expression and predicted
gene set function. Furthermore, machine learning approaches
failed to classify UISO cells as MCC, whereas other variant
cell lines were more similar to classic lines but were not
strongly classified as MCC. UISO also had an atypical
histopathologic phenotype when grown as xenograft tumors
in mice. At the same time, we found that the WaGa and Mkl-1
cell lines more closely resembled MCC tumors in gene
expression and in vivo growth.
In light of these findings, we speculate that an atypical MCC
tumor gave rise to the UISO cell line. UISO cells were derived
from a tumor arising on the thigh of a patient much younger
than the mean age for MCC presentation (46 vs. 72 years)
(Ronan et al., 1993). The primary tumor uncharac-
teristically failed to show chromogranin and MAK-6 pan-
cytokeratin staining but did have ENO2 and focal CAM5.2
staining. KRT20 staining was not assessed, as the antibody was
not in widespread use at the time. This immunophenotype in a
skin tumor is consistent with MCC but would not be
considered diagnostic by today’s standards. We found UISO
xenografts to be chromogranin negative, cytokeratin negative
by AE1/AE3 staining, negative for KRT20 staining, and possess-
ing sarcomatoid histologic features. The focal NCAM1 and
ENO2 staining in UISO xenografts was consistent with a
neuroendocrine tumor, possibly a poorly differentiated MCC.
UISO xenograft tumors did express CD99 (data not shown),
which is seen in peripheral primitive neuroectodermal
tumors. However, UISO cells did not have the canonical
t(11;22)(q24;q12) translocation associated with primitive
neuroectodermal tumors (Figure 5 and data not shown)
(Turc-Carel et al., 1988). Given the atypical nature of the
UISO tumor of origin, it is not surprising that the cell line is
atypical and possesses a transcriptome and in vivo biology
that is nonrepresentative of MCC tumors in general.
An atypical tumor of origin may not account for all the
uncharacteristic features of UISO or other variant MCC cell
lines. Even in typical MCC tumors, a minority subpopulation
of aberrant cells could exhibit a selective growth advantage in
culture. A cell line derived from such cells would not reflect
the average gene expression or biology of the MCC tumors. In
such a scenario, the subpopulation cells could still be
biologically important to tumor behavior, and having a cell
culture model of the atypical cells could potentially be
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Figure 5. Spectral karyotyping (SKY) of metaphase chromosomes confirms the identity of the UISO cell line. (a) Chromosomes stained with 4’,6-diamidino-2-
phenylindole (DAPI) and converted into G-banding-like appearance. (b) Chromosomes in display colors. (c) Chromosomes in classification colors. (d) UISO SKY
(with DAPI and classification images of each chromosome side by side). This cell has 46 chromosomes and contains previously described rearrangements,
including an insertion at 1p36.2, a cryptic insertion or duplication on 6q, a dicentric chromosome 8, and a small heterogeneous ring chromosome.
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instructive. Therefore, the UISO cell line and other nonrepre-
sentative cell lines may still prove useful in the study of cancer
biology.
In contrast to the variant lines, WaGa and Mkl-1 cells were
more representative of MCC tumors. Expression differences
relative to tumor tissue did exist with WaGa and Mkl-1 cells,
and this is expected because of the lack of stroma, vasculature,
and hematopoietic cells in cultured cancer cells. As a model
system to study the biology of MCC and predict the behavior
of native tumors, it appears that WaGa and Mkl-1 are
preferable to UISO or other variant lines.
A previous study comparing MCC cell lines using expres-
sion microarrays with only 1,083 genes found that UISO cells
clustered with classic MCC lines, such as Mkl-1 (Van Gele
et al., 2004). The limited scope of the genes analyzed and the
lack of MCC tumor samples likely contributed to this finding
that conflicts with our results. In contrast, using a com-
prehensive set of 440,000 human transcripts, we have
demonstrated through multiple analyses that UISO samples
cluster separately from both classic cell lines, as well as MCC
tumor samples.
It is interesting to note that on a transcriptome level, the set
of MCC tumor samples analyzed in this study are quite
homogeneous. Clustering of the expression data failed to
identify subclasses of MCC with strongly distinct gene expres-
sion signatures. We identified few differences in gene expres-
sion between MCV-positive and -negative tumor samples. This
contrasts with a recent publication comparing virus-positive
and virus-negative MCC tumors in which many more sig-
nificant differences were found (Harms et al., 2013). The
reason for these differing results is unknown. However, in their
study, only 46% of the tumors analyzed were found to be virus
positive, whereas most reports indicate that 70–80% of MCC
tumors are virus positive (Feng et al., 2008; Pulitzer et al.,
2009). This is more consistent with the 87% virus-positive
tumors we observed here. It is not clear whether this reflects a
difference in virus detection methods or a true difference in
the patient populations. Consistent with most prior studies, our
cohort had only a small number of virus-negative tumors.
Although we employed a robust technique for differential
gene expression detection that works well with small sample
sizes (Smyth, 2004, 2005), we cannot entirely rule out effects
because of sample size and class imbalance in our analysis.
Regardless, there was no concordance between the virus
status of the tumors and their dissimilarity to the variant cell
lines or their similarity to WaGa and Mkl-1, indicating that the
differences observed in the variant cell lines are not driven by
viral status.
The independence of tumor viral status on cell line
similarity is an important observation, as variant MCC cell
lines are predominantly MCV negative, and classic lines tend
to be MCV positive. All three variant cell lines used in this
study are MCV negative, whereas the classic lines are MCV
positive. By definition, variant lines lack expression of certain
differentiation markers, and our data suggest that variant cell
lines may be divergent from MCC tumors on a more general
level. However, the fact that MCV-negative native tumors are
not similarly distinct from MCV-positive tumors and classic
MCC cell lines suggests that MCV status alone is not the driver
of atypical gene expression in the variant cell lines. We have
demonstrated that the question of cell line representativeness
can be answered (in part) by the use of gene expression
microarray data. Straightforward computational methods and
publicly available data can be applied to compare cell lines
with native tumor tissue and other cell lines to assess cancer
type concordance. These types of techniques can, and should,
be applied when using existing lines or developing a new one.
With respect to MCC, our analysis suggests that representative
cell lines such as WaGa or Mkl-1 should be favored over
UISO, MCC13, or MCC16 as an in vitro experimental model.
MATERIALS AND METHODS
Ethics statement
All human research was conducted in accordance with approved
Institutional Review Board protocols. Patient specimens were col-
lected at Memorial Sloan Kettering Cancer Center under Institutional
Review Board protocol 00-144 A. All patients provided written
informed consent for the use of their sample for general research
purposes and did not specify limitations that restricted the use of their
samples for this study. Analysis of samples was conducted under
National Cancer Institute (NCI) Protocol 13CN024 without obtaining
further consent, as patients had provided prior consent and the
samples were analyzed anonymously. This study was performed in
strict accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the National Cancer Institute’s Animal
Care and Use Committee (Protocol DB-091).
MCV detection by real-time quantitative PCR
Primers were designed to amplify a region of the MCV T antigen
(coordinates 444–579 in the ‘‘MCV350’’ sequence GenBank Acces-
sion EU375803) to detect MCV DNA in MCC tumor samples by
quantitative PCR. Primers for b-actin (ACTB ), a gene on chromosome
7, were used as a reference on all MCC tumor samples.
Cell lines
The MCC cell lines Mkl-1 (Rosen et al., 1987), WaGa (Houben et al.,
2010), and UISO (Ronan et al., 1993) and MCC13 and MCC26
(Leonard et al., 1995) have been described previously. SK-MC01 cells
were generated at the Memorial Sloan Kettering Cancer Center.
Complementary DNA array hybridization of tumor samples and
cell lines
Fresh frozen tumor specimens were supplied by the Memorial Sloan
Kettering Cancer Center tumor bank. Total RNA was extracted from
tumor specimens and hybridized to Human Genome U133A 2.0
Array (Affymetrix, Santa Clara, CA) GeneChips.
Total RNA was extracted from three to six replicates of each cell
line (single replicate of MC01) and hybridized to the Human Genome
U133A 2.0 Array (Affymetrix). Three replicates of all cell lines
(excluding MC01) were also hybridized to the GeneChip Human
Genome U133 Plus 2.0 Array (Affymetrix).
Microarray analysis
For MCC tumors, SCLC tumors, and MCC cell lines on the Affymetrix
U133A 2.0 platform, normalization, filtering, and analysis of
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microarray expression data were performed using R (details in
Supplementary Methods online). Raw CEL files for CCLE data were
downloaded directly from Gene Expression Omnibus (accession
GSE36133) and were normalized as above with MCC cell line
Affymetrix U133 Plus 2.0 array data. We call probe sets to be
differentially expressed at a fold change of Z2 and qr0.05.
Classification of MCC cell lines with MCC and SCLC tumors
A random forest classifier was trained using the microarray expression
data for the 23 MCC and 9 SCLC tumor samples. The classifier was then
applied to the MCC cell lines, and the average class prediction was
determined for each of the MCC cell lines across sample replicates.
Classification of MCC cell lines with CCLE cell lines
A random forest classifier was trained using the microarray expression
data for MCC cell lines (except for UISO) along with samples from the
CCLE data set. The classifier was then applied to the variant (UISO,
MCC13, and MCC26) samples.
STR profiling
Genomic DNA was isolated from all cell lines and sent to the Johns
Hopkins Fragment Analysis Facility for STR profiling on all cell lines
except MCC13 and MCC26 using the AmpFlSTR Identifiler PCR
Amplification Kit (Applied Biosystems, Waltham, MA) that profiles 16
STR markers (Supplementary Table S7 online). MCC13 and MCC26
were profiled using the Promega (Fitchburg, WI) PowerPlex 18D Kit
that profiles the same 16 markers plus 2 others.
Mouse xenografts
Female NOD/SCID mice, 5 to 8 weeks old, were obtained from the
NCI Animal Production Program and housed under specific patho-
gen-free conditions. Tumors were induced by subcutaneous injection
of 107 WaGa cells, 2 107 Mkl-1 cells, or 106 UISO cells in 200ml
sterile saline into the posterior lateral flank of the mice. Tumor tissue
was collected and fixed in neutral buffered formalin after tumors were
clinically detectable.
Immunohistochemistry of mouse xenograft tumors
Paraffin-embedded tissue sections (5mm) of fixed xenograft tumors on
glass slides were stained on an automated immunostainer (Ventana
Medical Systems, Tucson, AZ) according to the manufacturer’s
instructions. The primary antibodies and antigen retrieval methods
used are indicated in Supplementary Table S8 online.
SKY of the UISO cell line
UISO cells were harvested after Colcemid (Life Technologies,
Waltham, MA) treatment (0.025mg ml 1: 12 hours) and processed
by standard cytogenetic methods. Breakpoints on the SKY-painted
chromosomes were determined by comparison with corresponding
inverted 4’,6-diamidino-2-phenylindole banding. We report SKY
results by using the International System for Human Cytogenetic
Nomenclature (ISCN, 2013).
Data access
All tumor samples and cell line microarray data have been deposited
in the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (Edgar et al., 2002) and are accessible through
Gene Expression Omnibus Series accession number GSE50451. All
analysis codes, including generation of all figures and tables, as well
as Supplementary Tables and Figures online, are available in refer-
ence Daily and Brownell (2014). See the Supplementary Methods
online for details.
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